Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEZS-108 vs doxorubicin as second-line therapy for advanced endometrial cancer
2012-005546-38Phase 3Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Aug 2013
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of zoptarelin doxorubicin in endometrial cancer (EC) (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoint: Overall survival. Started Aug 2013; status: completed.
02
Drugs
zoptarelin doxorubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2012-005546-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005546-38.